Transparency of public contributions to drug development
24 September 2025
| Journal article
Overview
The revised European pharmaceutical legislation (Article 57) will require market authorisation applicants to publicly declare any direct financial support received from public authorities for Research and Development (R&D) activities. Public contributions to drug R&D are numerous but remain poorly documented. Aligned public policies that enforce transparency in R&D investments are essential for implementing the transparency clause effectively. Although frameworks and methodologies for identifying and documenting public contributions to product R&D have been developed and applied in multiple case studies, the use of such data in price-setting and negotiations remains exploratory. Further policy options still need to be developed.
WHO Team
European Observatory on Health Systems and Policies
Editors
Claudia Wild and Daniel Fabian
Copyright
CC BY-NC-SA 3.0 IGO